2024: Mesoblast presents financial results, focusing on Remestemcel for steroid-refractory acute graft vs host disease and Rexlemestrocel for heart disease.
Mesoblast Limited (MESO) presented financial results and updates on Feb 29, 2024, highlighting focus on two key indications: Remestemcel (for pediatric & adult steroid-refractory acute graft vs host disease, with a larger potential adult market) and Rexlemestrocel (for heart disease). The company is developing novel allogeneic cell therapy technology platforms without donor matching or immunosuppression.
March 03, 2024
3 Articles